Faculty of Medicine, University of Oslo, Oslo, Norway.
Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
Biol Reprod. 2024 Aug 15;111(2):427-435. doi: 10.1093/biolre/ioae069.
Previous studies show differentially expressed long non-coding RNA present in the placenta from women with pre-eclampsia, potentially playing a vital role in the pathogenesis of the complication. In a published microarray study, Ribonuclease P RNA component H1 was decreased in leukocytes from women that later developed pre-eclampsia. We hypothesized that Ribonuclease P RNA component H1 decreased during pregnancy in women developing pre-eclampsia and important for the development of the complication. We isolated RNA from extracellular vesicles, leukocytes and plasma using blood samples taken at weeks 22-24 and 36-38 in women who subsequently developed pre-eclampsia and from healthy pregnancy. The expression of Ribonuclease P RNA component H1 was quantified using qPCR. Expression of Ribonuclease P RNA component H1 at 22-24 weeks was further examined to investigate its discriminatory potential of subsequent pre-eclampsia and association with clinical markers. We found lower expression of Ribonuclease P RNA component H1 in leukocytes at 22-24 and 36-38 weeks amongst women who subsequent developed pre-eclampsia compared with those who did not, while increased Ribonuclease P RNA component H1 expression was found in plasma at 36-38 weeks. Pre-eclampsia risk factors could not account for this difference in the Ribonuclease P RNA component H1 expression. Prediction of pre-eclampsia at 22-24 weeks using Ribonuclease P RNA component H1 expression in leukocytes in addition to the screening algorithm used today had a significantly better performance. In conclusion, Ribonuclease P RNA component H1 expression in leukocytes was significantly decreased in women with pre-eclampsia, and the expression at 22-24 weeks associated with the subsequent development of pre-eclampsia. Ribonuclease P RNA component H1 in leukocytes may be a useful biomarker for prediction and/or early detection of pre-eclampsia and an unknown regulator of the signaling affecting immune cells.
先前的研究表明,子痫前期妇女胎盘内存在差异表达的长非编码 RNA,这些 RNA 可能在该并发症的发病机制中发挥重要作用。在一项已发表的微阵列研究中,核糖核酸酶 P RNA 成分 H1 在随后发生子痫前期的女性白细胞中减少。我们假设,在发生子痫前期的女性怀孕期间,核糖核酸酶 P RNA 成分 H1 减少,并且对该并发症的发生很重要。我们使用在随后发生子痫前期的女性和健康妊娠的女性在 22-24 周和 36-38 周时采集的血液样本,从细胞外囊泡、白细胞和血浆中分离 RNA。使用 qPCR 定量检测核糖核酸酶 P RNA 成分 H1 的表达。进一步检查 22-24 周时核糖核酸酶 P RNA 成分 H1 的表达,以研究其对随后发生子痫前期的预测能力及其与临床标志物的关联。我们发现,与未发生子痫前期的女性相比,随后发生子痫前期的女性在 22-24 周和 36-38 周时白细胞中的核糖核酸酶 P RNA 成分 H1 表达较低,而在 36-38 周时血浆中的核糖核酸酶 P RNA 成分 H1 表达增加。子痫前期的危险因素不能解释核糖核酸酶 P RNA 成分 H1 表达的这种差异。除了今天使用的筛查算法外,使用白细胞中核糖核酸酶 P RNA 成分 H1 表达预测 22-24 周时的子痫前期具有显著更好的性能。总之,子痫前期妇女白细胞中的核糖核酸酶 P RNA 成分 H1 表达明显降低,22-24 周时的表达与随后发生子痫前期相关。白细胞中的核糖核酸酶 P RNA 成分 H1 可能是预测和/或早期发现子痫前期的有用生物标志物,也是影响免疫细胞的信号未知调节剂。